Therapeutic Areas & Pipeline

T2D and NASH are current areas of Therapeutic Focus at Connexios. Our pipeline comprises pre-clinical assets at various stages from qualified novel targets and early discovery to IND ready candidates. The targets and lead candidates have been selected based on their ability to fulfill unique Target Product Profiles (TPP’s) that can support the development of novel and highly differentiated drug candidates that can become valuable options for the treatment of T2D and NASH.

hover hover hover hover hover hover hover hover hover hover hover hover

CNX-011-67

click
Novel,best-in-class, insulinotropic agent that improves beta cell health and function to provide robust Glycemic control
Know More

CNX-012

click
Novel, potent agents that egulate cellular energy homeostasis store glucose & lipid metabolism cross multiple tissues to provide significant impact on Glucose, Lipid, CV risk parameters and body weight gain
Know More

CNX-010

click
Novel, potent and safe agent that correct the imbalance of tissue-specific cortisol levels to regulate metabolism alterations along with CV rids and body weight gain in overweight / obese diabetics
Know More

CNX-013

click
Novel, selective and safe agents that robustlyregulate glucose and lipid metabolism directly across key tissues thereby improve systemic insulin sensitivity & reduce bodyweight gainto provide long term benefits inCV risk parameters
Know More

Please visit Business Strategy page to view current opportunities and to request non-confidential information on our programs.